尽管兴趣短浅,但 " 蓝图药品 " 保留了积极的分析师评级和目标。 Despite increased short interest, Blueprint Medicines retains positive analyst ratings and targets.

1 月份，Blueprint Medicines（纳斯达克股票代码：BPMC）的空头股数上涨 12.6% 至 510 万股。 In January, short interest in Blueprint Medicines (NASDAQ: BPMC) rose by 12.6% to 5.1 million shares. 尽管如此,分析师仍保持乐观的前景,从“买入”到“市场超额业绩”的评级不一,平均价格目标为123.56美元。 Despite this, analysts maintain positive outlooks, with ratings ranging from "buy" to "market outperform," and an average price target of $123.56. 过去三个月内,内幕出售了49 000多股股票,价值近500万美元。 Insiders sold over 49,000 shares in the last three months, worth nearly $5 million. 该公司开发治疗基因界定的癌症和血液紊乱的药物。 The company develops medicines for genomically defined cancers and blood disorders.